TY - JOUR
T1 - Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival
AU - Guerrico, Anatilde Gonzalez
AU - Hillman, David
AU - Karnes, Jeffery
AU - Davis, Brian
AU - Gaston, Steven
AU - Klee, George
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Support for this study was provided by the Mayo Clinic Prostate SPORE grant NIH/NCI CA091956 and Beckman Coulter, Inc. to Dr Klee.
Funding Information:
Support for this study was provided by the Mayo Clinic Prostate SPORE grant NIH/NCI CA091956 and Beckman Coulter, Inc. to Dr Klee.
Publisher Copyright:
© The Author(s) 2017.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Free human kallikrein 2 (free-hK2) and hK2 pro-form (pro-hK2) have been found to be increased in tumor tissues and serum from patients with prostate cancer. We established semiautomatic assays for free-hK2 and pro-hK2 using a research version of the Beckman Coulter ACCESS2 system. Serum samples from a cohort of 189 men undergoing radical prostatectomy for known high-risk disease were assayed for Prostate-Specific Antigen (PSA), free-PSA, free-hK2, and prohK2. Univariate Cox regression and multivariate models were used to predict both Gleason scores and progression-free survival (PFS). Free-hk2 levels ≥80 ng/L were predictive of both Gleason scores ≥7 (p = 0.04) and PFS (p = 0.03). PSA ≥8.0 μg/L also was predictive of PFS (p = 0.02). However, neither % free-PSA nor pro-hK2, when treated as continuous or cutoff variables were associated with Gleason score or PFS. Multivariable models showed that clinical stage T1c versus T2/T3, Gleason score ≥7, and PSA≥8.0 μg/L or clinical stage T1c versus T2/T3, Gleason scores ≥7, and free-hK2 ≥ 80 ng/L were among the best models predicting PFS. Both free-hK2 and PSA in conjunction with clinical stage and Gleason score are good predictors of PFS in prostate cancer.
AB - Free human kallikrein 2 (free-hK2) and hK2 pro-form (pro-hK2) have been found to be increased in tumor tissues and serum from patients with prostate cancer. We established semiautomatic assays for free-hK2 and pro-hK2 using a research version of the Beckman Coulter ACCESS2 system. Serum samples from a cohort of 189 men undergoing radical prostatectomy for known high-risk disease were assayed for Prostate-Specific Antigen (PSA), free-PSA, free-hK2, and prohK2. Univariate Cox regression and multivariate models were used to predict both Gleason scores and progression-free survival (PFS). Free-hk2 levels ≥80 ng/L were predictive of both Gleason scores ≥7 (p = 0.04) and PFS (p = 0.03). PSA ≥8.0 μg/L also was predictive of PFS (p = 0.02). However, neither % free-PSA nor pro-hK2, when treated as continuous or cutoff variables were associated with Gleason score or PFS. Multivariable models showed that clinical stage T1c versus T2/T3, Gleason score ≥7, and PSA≥8.0 μg/L or clinical stage T1c versus T2/T3, Gleason scores ≥7, and free-hK2 ≥ 80 ng/L were among the best models predicting PFS. Both free-hK2 and PSA in conjunction with clinical stage and Gleason score are good predictors of PFS in prostate cancer.
KW - Free-hK2
KW - PSA
KW - Pro-hK2
KW - Progression-free survival
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85037368874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037368874&partnerID=8YFLogxK
U2 - 10.1177/1849454417720151
DO - 10.1177/1849454417720151
M3 - Article
AN - SCOPUS:85037368874
SN - 1849-4544
VL - 6
JO - Journal of Circulating Biomarkers
JF - Journal of Circulating Biomarkers
ER -